Giannis S. Mountzios, MD, on Metastatic PD-L1–High NSCLC: Sacituzumab Govitecan/Pembrolizumab

October 05, 2026

Giannis S. Mountzios, MD, of Henry Dunant Hospital Center, reviews primary results from the phase III EVOKE-03/KEYNOTE D46 trial, which evaluated first-line sacituzumab govitecan in combination with pembrolizumab in patients with metastatic non–small cell lung cancer (NSCLC) and a PD-L1 tumor proportion score of 50% or higher (Abstract PL02.06). 

Related Content